全文获取类型
收费全文 | 128325篇 |
免费 | 13930篇 |
国内免费 | 7514篇 |
专业分类
耳鼻咽喉 | 1089篇 |
儿科学 | 2215篇 |
妇产科学 | 1485篇 |
基础医学 | 13127篇 |
口腔科学 | 2790篇 |
临床医学 | 16538篇 |
内科学 | 16768篇 |
皮肤病学 | 1582篇 |
神经病学 | 5857篇 |
特种医学 | 4593篇 |
外国民族医学 | 38篇 |
外科学 | 10588篇 |
综合类 | 24844篇 |
现状与发展 | 34篇 |
一般理论 | 9篇 |
预防医学 | 11850篇 |
眼科学 | 3403篇 |
药学 | 15005篇 |
186篇 | |
中国医学 | 9139篇 |
肿瘤学 | 8629篇 |
出版年
2024年 | 582篇 |
2023年 | 1830篇 |
2022年 | 4603篇 |
2021年 | 5845篇 |
2020年 | 4876篇 |
2019年 | 3581篇 |
2018年 | 3875篇 |
2017年 | 4296篇 |
2016年 | 3539篇 |
2015年 | 5580篇 |
2014年 | 6918篇 |
2013年 | 7609篇 |
2012年 | 10609篇 |
2011年 | 11186篇 |
2010年 | 8080篇 |
2009年 | 6635篇 |
2008年 | 7614篇 |
2007年 | 7254篇 |
2006年 | 6635篇 |
2005年 | 5235篇 |
2004年 | 3749篇 |
2003年 | 3446篇 |
2002年 | 2677篇 |
2001年 | 3849篇 |
2000年 | 3375篇 |
1999年 | 2638篇 |
1998年 | 1108篇 |
1997年 | 865篇 |
1996年 | 613篇 |
1995年 | 571篇 |
1994年 | 458篇 |
1993年 | 323篇 |
1992年 | 1087篇 |
1991年 | 964篇 |
1990年 | 871篇 |
1989年 | 928篇 |
1988年 | 856篇 |
1987年 | 776篇 |
1986年 | 707篇 |
1985年 | 621篇 |
1984年 | 390篇 |
1983年 | 320篇 |
1982年 | 185篇 |
1981年 | 147篇 |
1980年 | 120篇 |
1979年 | 210篇 |
1973年 | 94篇 |
1972年 | 95篇 |
1971年 | 94篇 |
1970年 | 90篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
目的在比较自发性高血压大鼠(SHR)与同龄无高血压Wistar大鼠永久性大脑中动脉阻塞(pMCAO)后脑缺血损伤情况并初步分析其可能机制。方法雄性SHR和Wistar大鼠各30只分别随机分为:pMCAO模型6 h组、假手术6 h组、pMCAO模型24 h组、假手术24 h组和正常组(均n=6)。采用线栓法制作pMCAO模型,术后6、24 h对大鼠进行神经功能学评分后处死,制作脑冠状切片。术后6 h处死大鼠脑部切片行尼氏染色后在组织学层面上观察神经元损伤情况;术后24 h处死大鼠脑部切片行尼氏染色后计算脑梗死体积和水肿程度百分比。正常组脑部切片经苏木精-伊红染色后计算脑部小血管壁/腔比。结果术后6和24 h,不同品系大鼠神经功能学评分差异无统计学意义(P0.05);术后6 h尼氏染色示SHR神经元损伤重于Wistar大鼠。术后24 h SHR脑梗死体积百分比[(28.05±2.38)%]大于Wistar大鼠[(25.23±1.33)%],差异有统计学意义(P0.05)。两品系大鼠之间脑水肿程度差异无显著性。脑部小血管壁/腔比SHR[(11.46±3.74)%]较Wistar大鼠[(8.73±1.73)%]增大(P0.05)。结论 pMCAO术后SHR的脑缺血损伤程度重于Wistar大鼠,可能与高血压引起的脑侧支循环血管壁增厚、僵硬,自我调节能力降低有关。 相似文献
43.
44.
Jing Yang Changqing Liu Linxia Zhang Yanhui Liu Aihua Guo Huiwu Shi Xiaoxia Liu Ying Cheng 《Inflammation》2015,38(4):1415-1423
45.
46.
Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer’s Disease
In order to solve the problem of long-term (>9 months) efficacy in the treatment of Alzheimer''s disease (AD) by conventional therapy (CT), a staged and multiply-targeted sequential therapy based on the evolvement of patterns (STEP) was developed. Its main innovations include: (1) the time order of evolution of patterns defined by Chinese medicine (CM) in AD was found, that is, "the orderly pattern evolution starting from Shen (Kidney) deficiency, progressing to phlegm, stasis and fire, and worsening to severe toxin as well as functional collapse"; (2) the cascade hypothesis of Shen deficiency in AD and its sequential therapy based on Shen-reinforcing was proposed, that is, "reinforcing Shen in the early stage and throughout the whole process, resolving phlegm, activating blood and purging fire in the middle stage, detoxifying and replenishing vitality to stop the collapse in the advanced stage", and through meta-analysis, clinical drug use was optimized, thus the leap from "inferential selection" to "evidence-based selection" was realized; (3) the STEP regimen combined with CT maintained cognitive and behavioral stability in AD patients for at least 12 months, with cognitive enhancement and behavioral synergy after 9 months, and cognitive benefit was superior to CT at 9, 12, 15, 18, 21, and 24 months, respectively. The 2-year cognitive improvement rate was increased by 25.64% (P=0.020) and the cognitive deterioration rate was decreased by 48.71% (P=0.000). Among them, the cognitive and functional benefits of Shen-reinforcing therapy for very early AD (350 cases) for 1 year were better than the placebo (P<0.001), and the dementia conversion rate was reduced by 8.85% (P=0.002). The behavioral symptomatic relief of patients with vascular dementia received fire-purging therapy (540 cases) was superior to those received CT (P=0.016). These data suggested that the STEP regimen has synergistic effects on CTs at least in terms of cognitive benefit, and the earlier the use, the greater the benefit will have. Therefore, the STEP regimen should be considered as one of the clinical options, particularly for the dearth of effective pharmaceutical or immunological interventions that are currently available for AD. 相似文献
47.
48.
49.
50.